Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

Jen-Je Chieh, K. W. Huang, C. P. Chuang, W. C. Wei, J. J. Dong, Y. Y. Lee

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

原文英語
文章編號7273866
頁(從 - 到)1681-1686
頁數6
期刊IEEE Transactions on Biomedical Engineering
63
發行號8
DOIs
出版狀態已發佈 - 2016 八月 1

指紋

Biomarkers
Hepatocellular Carcinoma
Assays
Screening
alpha-Fetoproteins
Enzymes
Magnetic variables measurement
Enzyme-Linked Immunosorbent Assay
Antigens
Iron oxides
Antibodies
Rats
Tumors
Animals
acarboxyprothrombin
Nanoparticles
Buffers
Sensitivity and Specificity
Neoplasms
Immunosorbents

ASJC Scopus subject areas

  • Biomedical Engineering

引用此文

Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma. / Chieh, Jen-Je; Huang, K. W.; Chuang, C. P.; Wei, W. C.; Dong, J. J.; Lee, Y. Y.

於: IEEE Transactions on Biomedical Engineering, 卷 63, 編號 8, 7273866, 01.08.2016, p. 1681-1686.

研究成果: 雜誌貢獻文章

Chieh, Jen-Je ; Huang, K. W. ; Chuang, C. P. ; Wei, W. C. ; Dong, J. J. ; Lee, Y. Y. / Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma. 於: IEEE Transactions on Biomedical Engineering. 2016 ; 卷 63, 編號 8. 頁 1681-1686.
@article{da6f51b3925f4c10bc82ee3f2ade1e19,
title = "Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma",
abstract = "The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.",
keywords = "Des-gamma-carboxy prothrombin, enzyme-linked, hepatocellular carcinoma, immunomagnetic reduction, immunosorbent assay",
author = "Jen-Je Chieh and Huang, {K. W.} and Chuang, {C. P.} and Wei, {W. C.} and Dong, {J. J.} and Lee, {Y. Y.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1109/TBME.2015.2478845",
language = "English",
volume = "63",
pages = "1681--1686",
journal = "IEEE Transactions on Biomedical Engineering",
issn = "0018-9294",
publisher = "IEEE Computer Society",
number = "8",

}

TY - JOUR

T1 - Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

AU - Chieh, Jen-Je

AU - Huang, K. W.

AU - Chuang, C. P.

AU - Wei, W. C.

AU - Dong, J. J.

AU - Lee, Y. Y.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

AB - The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

KW - Des-gamma-carboxy prothrombin

KW - enzyme-linked

KW - hepatocellular carcinoma

KW - immunomagnetic reduction

KW - immunosorbent assay

UR - http://www.scopus.com/inward/record.url?scp=84986270047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986270047&partnerID=8YFLogxK

U2 - 10.1109/TBME.2015.2478845

DO - 10.1109/TBME.2015.2478845

M3 - Article

C2 - 26415145

AN - SCOPUS:84986270047

VL - 63

SP - 1681

EP - 1686

JO - IEEE Transactions on Biomedical Engineering

JF - IEEE Transactions on Biomedical Engineering

SN - 0018-9294

IS - 8

M1 - 7273866

ER -